EUROPE WILL GRADUALLY OPEN UP OVER THE NEXT THREE YEARS TO BECOME THE LARGEST LEGAL CANNABIS MARKET IN THE WORLD.
We provide market intelligence and strategic consultancy to investors, entrepreneurs and regulators who are ready to embrace opportunity in this emerging frontier.
Our reliable and credible insight is maturing the conversation and opening up the market.
MArket Data & Insights
Ongoing free reports and content including The European Cannabis Report™ and European Cannabis Weekly newsletter.
Detailed research and analysis for both regulators and investors interested in the potential of the European market.
Market entry and expansion strategy including regulatory relationships, licensing applications and cross border commerce
MGC Pharmaceuticals secure a European cannabis manufacturing license for a facility in Slovenia, whilst elsewhere, XHemplar plant up 25 acres of ‘cannabis light’ in Italy. Meanwhile, Genetically modified cannabis may be close to a breakthrough, and Prohibition Partners announce the release of The European Cannabis Report™ 3rd Edition.
Crop signs an agreement to cultivate over half a million square feet of ‘cannabis 'light’ in Italy, while elsewhere Maricann receives a letter of intent from Malta Enterprise, allowing them to move ahead with licensing. Meanwhile, Switzerland’s government proposes medical cannabis pilot programmes and the UK opposition calls for cannabis decriminalisation.
Aurora becomes the first licensed supplier to the Maltese medical cannabis industry, while Canopy CEO Bruce Linton suggests that future of cannabis may be as product, not as a commodity. Elsewhere, Luxembourg votes in favour of legalising medical cannabis, as Britain inches closer to a regulated medical market.
The UK prepares for cannabis reform after a landmark week in the news, and a number of high-profile medical cannabis cases. Meanwhile, Malta issues its first import licence to Aphira subsidiary, ASG Pharma, and Speakeasy Cannabis Clubs look to expand into the German market.
Parisians line up to buy low-THC ‘cannabis light’ in newly opened store, while German insurers release their first insights into the business of covering medical cannabis. Elswhere, UK border force confiscates ‘openly smuggled’ cannabis oil from Charlotte Caldwell, as she attempts to treat her severely epileptic son.
A new study finds that legalising cannabis could boost UK tax revenue by up to £3.5 billion per year, while the global drinks industry, suggests cannabis is its single biggest threat. Meanwhile, after weeks of raids, Denmark’s Freetown Christiania market finally concedes and stops selling cannabis. Also in the news is an early test suggesting that cannabis could effectively treat symptoms of Lyme disease.
GW Pharma makes a breakthrough with US Food and Drug Administration, while Aurora heavily expands it’s German market presence. Meanwhile, a new study finds that the majority of Britons would prefer a softer stance on cannabis, as the French Health Minister suggests medical cannabis could be on its way…
MGC plans 4,000 square metre facility in Malta in attempt to penetrate the European market, whilst Doctors lead a protest in House of Commons to overturn Britains medical cannabis ban. Elsewhere, a Scottish petition approaches it’s target to trigger parliamentary debate.
Aurora buys Medreleaf for €1.9 billion in the largest cannabis merger to date. Canadian companies look abroad as industry consolidation continues, the UK’s first not for profit CBD shop opens in Edinburgh, and Thailand looks towards a legal medical cannabis market.
Maricaan Group closes the acquisition of Swiss company Haxxon, as Organigram sets up to acquire 25% of German company Alpha-Cannabis. Marches in Peru and Argentina demand new cannabis laws, while the British Medical Journal argues for legalised, regulated and taxed cannabis. Meanwhile, new studies suggest cannabis could treat anxiety, depression and PTSD.
Since March 2017, medical cannabis has been legal in Germany, launching a new domestic industry, and attracting the watchful eye of the global cannabis community.
Previously, the state had only accepted applications from around 1,000 patients who had navigated rigorous regulations in order to legally access cannabis treatments. However, as of March 2018, the number of applications to the health insurance companies has risen to 13,000, with over 60% of requests for reimbursement being approved.
Dutch cannabis laws are not without fault. Since the introduction of coffee shops in 1976, Amsterdam’s cannabis has been supplied by criminal organisations. Additionally, a lack of cannabis cultivation licences, since 2003, has allowed Bedrocan to develop a monopoly. But as the global reform on cannabis begins, the Netherlands are experimenting with cultivation licences in a bid to grow the industry.
France is emblematic of the hypocritical cannabis policies exhibited in Western Europe. More people consume cannabis in France than anywhere else in Europe, but despite recent amendments to the 1970 cannabis law, France is still missing out on a hugely profitable market.
Starting in the 1960s, Finland, like its Scandinavian neighbours developed a history of drug prohibition. However, Finland is too often tarred with the same brush as Sweden’s repressive policies. In reality, since 2008, Finland has legalised medical cannabis and reformed the formerly punitive cannabis policies. Although mainstream politics avoids the subject of full legalisation, youth parties are fighting for reform in the happiest country in the world.
In Sweden medical cannabis use has been considered an aggravating circumstance rather than an extenuating circumstance as many patients have suffered at the hands of punitive state laws. However, as two historic cannabis licences have been granted, Sweden may no longer be able to remain an island in the changing global consensus on cannabis.
On the whole, public policies in the Nordic countries are usually informed by modern science and human rights. Drug policy is, arguably, the notable exception. Current cannabis laws in Norway are not based on any real science of humanism but largely as a result of the fearmongering rhetoric of the 60s and 80s. However, as much of Europe rolls back the embargo on medical cannabis, Norway is looking to differentiate itself from the typically repressive Scandinavian cannabis policies.
Estonia is starkly juxtaposed with the rest of Europe in the medical cannabis space. On one side, the state are surprisingly keen to implement some form of medical cannabis system but on the other, caution and anxiety pervade mainstream public opinion on cannabis reform.